Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib (PAGIST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01524848
Recruitment Status : Completed
First Posted : February 2, 2012
Last Update Posted : May 10, 2017
Information provided by (Responsible Party):
Scandinavian Sarcoma Group

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : January 2015
  Study Completion Date : November 2016